Targeting EGFR in in glioblastoma with a novel brain-penetrant small molecule EGFR-TKI

Time: 12:10 pm
day: Day Two


  • A novel EGFR-TKi with extraordinary brain-selective distribution ( >20-fold brain to plasma ratio)
  • It has a favorable oral PK and safety profile with a low systemic toxicity
  • Superior activity against GBM in preclinical models (patient-derived and GEM models)